Entrada Therapeutics (TRDA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TRDA SEC filings page.
Entrada Therapeutics, Inc. (TRDA) reported $4.7M in revenue over the twelve months to Jun 30, 2026, down 94.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Entrada’s economics are development-stage: revenue collapsed while research spending stayed high, leaving cash generation closely tied to funding and reported earnings quality.
Profit and cash did not consistently agree: FY2024 reported net income of$65.6M alongside operating cash flow of-$41.6M , indicating that earnings were not converting into operating cash. By FY2025, a net loss of$143.8M was accompanied by operating cash flow of-$128.5M , making the underlying cash cost of development much clearer.
FY2025 revenue fell
Funding became less supportive: financing cash flow fell to
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Entrada Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Entrada Therapeutics, Inc. held $90.4M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $128.5M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Entrada Therapeutics, Inc. scores 28/100 among other emerging companies.
Entrada Therapeutics, Inc. had 38M shares outstanding at the end of fiscal year 2025, against 38M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Entrada Therapeutics, Inc. scores 55/100 among other emerging companies.
Entrada Therapeutics, Inc. spent $142.3M on research and development in fiscal year 2025, which was 77.6% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Entrada Therapeutics, Inc. scores 95/100 among other emerging companies.
Entrada Therapeutics, Inc. reported revenue of $25.4M in fiscal year 2025, against $210.8M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Entrada Therapeutics, Inc. scores 4/100 among other emerging companies.
Not available for Entrada Therapeutics, Inc., so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.
Entrada Therapeutics, Inc.'s cash, cash equivalents and investments came to $90.4M at the end of fiscal year 2025, against $71.2M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Entrada Therapeutics, Inc. scores 66/100 among other emerging companies.
Entrada Therapeutics, Inc. scores 0.02, below the 1.81 distress threshold. The score is pulled down most by an operating loss of $157.9M against total assets of $377.4M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Entrada Therapeutics, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.
Entrada Therapeutics, Inc. reported a net loss of $143.8M while operations used $128.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Entrada Therapeutics, Inc. generated $898K in revenue in Q2 2026. This represents a decrease of 53.9% from the same quarter a year earlier. Against the prior quarter it is up 2.6%.
Entrada Therapeutics, Inc.'s EBITDA was -$44.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Entrada Therapeutics, Inc. reported a net loss of $42.8M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Entrada Therapeutics, Inc. earned -$1.01 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Entrada Therapeutics, Inc. recorded an outflow of $32.5M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Entrada Therapeutics, Inc. held $99.3M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Margins & Returns
Entrada Therapeutics, Inc.'s quarterly ROE was -18.3% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 7.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.7 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Entrada Therapeutics, Inc. invested $35.4M in research and development in Q2 2026. This represents a decrease of 6.6% from the same quarter a year earlier. Against the prior quarter it is up 7.0%.
Entrada Therapeutics, Inc. invested $11K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 96.0% from the same quarter a year earlier. Against the prior quarter it is down 75.0%.
Not reported for Q2 2026.
TRDA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $898K-53.9% | $875K-95.7% | $1.3M-96.5% | $1.6M-91.8% | $1.9M-97.9% | $20.6M-65.2% | $37.4M-10.6% | $19.6M-55.3% |
| R&D Expenses | $35.4M-6.6% | $33.1M+3.1% | $34.0M+1.6% | $38.4M+22.7% | $37.9M+18.2% | $32.1M+12.1% | $33.4M+18.1% | $31.3M+40.9% |
| SG&A Expenses | $10.5M-3.9% | $10.1M-1.5% | $9.6M-3.1% | $10.3M+3.3% | $10.9M+18.3% | $10.3M+9.3% | $9.9M+14.0% | $10.0M+32.4% |
| Operating Income | -$45.0Mn/m | -$42.3Mn/m | -$42.2Mn/m | -$47.1Mn/m | -$46.8M-187.7% | -$21.8M-203.2% | -$5.9M-219.6% | -$21.7M-254.6% |
| EBITDA | -$44.2Mn/m | -$41.5Mn/m | -$41.4Mn/m | -$45.9Mn/m | -$45.7M-184.2% | -$20.8M-194.5% | -$4.8M-184.6% | -$20.8M-240.1% |
| Income Tax | $35K-80.3% | $38Kn/m | $92Kn/m | $654Kn/m | $178K-93.5% | $0-100.0% | -$1.9M-110.0% | -$1.9Mn/m |
| Net Income | -$42.8Mn/m | -$39.7Mn/m | -$39.2M-3562.8% | -$44.1Mn/m | -$43.1M-178.3% | -$17.3M-173.8% | $1.1Mn/m | -$14.0M-139.6% |
| EPS (Basic) | -$1.01n/m | -$0.95n/m | -$0.94n/m | -$1.06n/m | -$1.04-164.6% | -$0.42-160.0% | -$0.03n/m | -$0.35-132.7% |
| EPS (Diluted) | -$1.01n/m | -$0.95n/m | -$0.94n/m | -$1.06n/m | -$1.04-167.1% | -$0.42-161.8% | -$0.04n/m | -$0.35-134.3% |
| Diluted Shares (Avg) | 42M+2.1% | 42M+1.9% | N/A | 41M+2.1% | 41M+16.4% | 41M+18.1% | N/A | 41M+16.8% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
TRDA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $298.9M-33.4% | $335.5M-31.0% | $377.4M-28.3% | $412.9M-25.5% | $448.8M-22.9% | $486.5M-4.8% | $526.3M+12.2% | $554.6M+14.3% |
| Current Assets | $232.7M-37.0% | $266.9M-33.8% | $306.3M-30.4% | $338.3M-27.3% | $369.1M-24.6% | $403.2M-2.7% | $440.0M+19.0% | $465.3M+21.5% |
| Cash & Equivalents | $99.3M+37.0% | $76.4M+12.7% | $90.4M-10.7% | $93.3M+19.5% | $72.5M-60.9% | $67.8M-0.9% | $101.2M+49.7% | $78.0M+50.4% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $65.5M-5.5% | $64.7M-6.6% | $71.2M-27.0% | $72.2M-45.4% | $69.3M-54.4% | $69.2M-71.3% | $97.6M-57.0% | $132.1M-44.6% |
| Current Liabilities | $21.4M+7.9% | $19.2M+4.1% | $24.5M-38.1% | $24.0M-66.0% | $19.8M-76.9% | $18.4M-89.4% | $39.5M-75.1% | $70.6M-57.3% |
| Non-Current Liabilities | $44.1M-10.9% | $45.5M-10.5% | $46.8M-19.5% | $48.2M-21.7% | $49.5M-25.3% | $50.8M-24.8% | $58.2M-14.5% | $61.5M-15.6% |
| Total Equity | $233.4M-38.5% | $270.9M-35.1% | $306.1M-28.6% | $340.7M-19.3% | $379.5M-11.7% | $417.3M+54.9% | $428.7M+76.9% | $422.4M+71.3% |
| Retained Earnings | -$355.6Mn/m | -$312.8Mn/m | -$273.1Mn/m | -$233.9Mn/m | -$189.8Mn/m | -$146.7Mn/m | -$129.3Mn/m | -$130.5Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
TRDA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$32.5Mn/m | -$41.7Mn/m | -$32.2Mn/m | -$28.3Mn/m | -$29.5M-174.0% | -$38.5Mn/m | -$31.6Mn/m | -$24.3Mn/m |
| Depreciation & Amortization | $800K-27.3% | $805K-14.9% | $886K-10.7% | $1.2M+33.3% | $1.1M+22.2% | $946K+1.3% | $992K+34.8% | $900K+12.5% |
| Stock-Based Compensation | $5.2M+2.0% | $4.7M-6.7% | N/A | $5.1M+5.3% | $5.0M+9.2% | $5.1M+36.3% | N/A | $4.9M+43.1% |
| Capital Expenditures | $11K-96.0% | $44K-96.2% | -$207K-67.4% | -$171K-73.2% | $275K-73.7% | $1.1M+36.5% | $635K-34.9% | $639K-55.9% |
| Free Cash Flow | -$32.5Mn/m | -$41.7Mn/m | -$32.4Mn/m | -$28.5Mn/m | -$29.8M-176.7% | -$39.7Mn/m | -$32.2Mn/m | -$24.9Mn/m |
| Investing Cash Flow | $54.9M+62.6% | $27.0M+464.2% | $29.1M-45.4% | $49.1Mn/m | $33.8Mn/m | $4.8M-81.7% | $53.4M+180.2% | -$82.9Mn/m |
| Financing Cash Flow | $350K+3.9% | $100K-71.4% | $192K-86.3% | $8Kn/m | $337K-99.7% | $350K+69.9% | $1.4M+103.2% | -$11K-103.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TRDA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -5007.0% | -4834.6% | -3249.3% | -2915.2% | -2402.5% | -106.0% | -15.7%-27.4pp | -110.7% |
| Net Margin | -4762.0% | -4539.1% | -3014.9% | -2734.4% | -2210.4% | -84.4%-124.1pp | 3.0%+25.8pp | -71.7%-152.8pp |
| Return on Equity | -18.3%-7.0pp | -14.7%-10.5pp | -12.8%-13.1pp | -13.0%-9.6pp | -11.4%-24.2pp | -4.2%-12.9pp | 0.3%+4.2pp | -3.3%-17.7pp |
| Return on Assets | -14.3%-4.7pp | -11.8%-8.3pp | -10.4%-10.6pp | -10.7%-8.2pp | -9.6%-19.1pp | -3.6%-8.2pp | 0.2%+2.2pp | -2.5%-9.8pp |
| Current Ratio | 10.89-7.8x | 13.90-8.0x | 12.53+1.4x | 14.08+7.5x | 18.64+12.9x | 21.88+19.5x | 11.15+8.8x | 6.59+4.3x |
| Liabilities-to-Equity | 0.28+0.1x | 0.24+0.1x | 0.230.0x | 0.21-0.1x | 0.18-0.2x | 0.17-0.7x | 0.23-0.7x | 0.31-0.7x |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.00-0.1x | 0.000.0x | 0.00-0.2x | 0.04-0.1x | 0.070.0x | 0.04-0.1x |
| FCF Margin | -3616.3% | -4770.2% | -2495.0% | -1764.8% | -1526.4% | -192.9% | -86.2%-74.3pp | -127.3% |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Entrada Therapeutics, Inc. TRDA | FY2025 | $25.4M | -$143.8M | N/A | $171.7M | 50/100 |
| Tiziana Life Sciences Ltd. TLSA | FY2025 | N/A | -$18.4M | N/A | $111.0M | — |
| Tenaya Therapeutics, Inc. TNYA | FY2025 | N/A | -$90.6M | N/A | $91.5M | — |
| Cognition Therapeutics, Inc. CGTX | FY2025 | N/A | -$23.5M | N/A | $72.2M | — |
| Eupraxia Pharmaceuticals Inc. EPRX | FY2025 | $0 | -$38.6M | N/A | $467.8M | — |
| C4 Therapeutics, Inc. CCCC | FY2025 | $35.9M | -$105.0M | N/A | $394.9M | 65/100 |
Where Entrada Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Entrada Therapeutics, Inc.'s annual revenue?
Entrada Therapeutics, Inc. (TRDA) reported $25.4M in total revenue for fiscal year 2025. This represents a -87.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Entrada Therapeutics, Inc.'s revenue growing?
Entrada Therapeutics, Inc. (TRDA) revenue declined by 87.9% year-over-year, from $210.8M to $25.4M in fiscal year 2025.
Is Entrada Therapeutics, Inc. profitable?
No, Entrada Therapeutics, Inc. (TRDA) reported a net loss of $165.8M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $143.8M.
What is Entrada Therapeutics, Inc.'s EBITDA?
Entrada Therapeutics, Inc. (TRDA) had EBITDA of -$153.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Entrada Therapeutics, Inc.'s return on equity (ROE)?
Entrada Therapeutics, Inc. (TRDA) has a return on equity of -47.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Entrada Therapeutics, Inc.'s free cash flow?
Entrada Therapeutics, Inc. (TRDA) recorded an outflow of $129.6M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Entrada Therapeutics, Inc.'s operating cash flow?
Entrada Therapeutics, Inc. (TRDA) recorded an outflow of $128.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Entrada Therapeutics, Inc.'s total assets?
Entrada Therapeutics, Inc. (TRDA) had $377.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Entrada Therapeutics, Inc.'s capital expenditures?
Entrada Therapeutics, Inc. (TRDA) invested $1.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Entrada Therapeutics, Inc. spend on research and development?
Entrada Therapeutics, Inc. (TRDA) invested $142.3M in research and development during fiscal year 2025.
What is Entrada Therapeutics, Inc.'s current ratio?
Entrada Therapeutics, Inc. (TRDA) had a current ratio of 12.53 as of fiscal year 2025, which is generally considered healthy.
What is Entrada Therapeutics, Inc.'s liabilities-to-equity ratio?
Entrada Therapeutics, Inc. (TRDA) had a liabilities-to-equity ratio of 0.23 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Entrada Therapeutics, Inc.'s return on assets (ROA)?
Entrada Therapeutics, Inc. (TRDA) had a return on assets of -38.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Entrada Therapeutics, Inc.'s P/E ratio?
Entrada Therapeutics, Inc. (TRDA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $171.7M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Entrada Therapeutics, Inc.'s price-to-sales ratio?
Entrada Therapeutics, Inc. (TRDA) trades at 36.6x sales, its market capitalization divided by $4.7M revenue, trailing 12 months to June 30, 2026. The market capitalization is $171.7M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Entrada Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Entrada Therapeutics, Inc. (TRDA) held $90.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $128.5M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Entrada Therapeutics, Inc.'s Altman Z-Score?
Entrada Therapeutics, Inc. (TRDA) has an Altman Z-Score of 0.02, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Entrada Therapeutics, Inc.'s Piotroski F-Score?
Entrada Therapeutics, Inc. (TRDA) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Entrada Therapeutics, Inc.'s earnings high quality?
Entrada Therapeutics, Inc. (TRDA) reported a net loss of $143.8M while operations used $128.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Entrada Therapeutics, Inc.?
Entrada Therapeutics, Inc. (TRDA) scores 50 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Entrada Therapeutics, Inc. it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.